Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

itional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release

and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of thes
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... CEL-SCI Corporation (NYSE AMEX: CVM ... treatment for the "swine flu and related H1N1" flu ... System) vaccine technology. The Company plans to utilize ... protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a ...
... and AMSTERDAM, May 26 ,Agendia, a world leader ... its U.S. clinical genomics laboratory in Huntington Beach, ... Clinical Laboratory,Improvements Amendments (CLIA) as administered by the ... In addition to opening its ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: ... and supplier,of branded generic and innovative pharmaceuticals ... a 37.5% stake in Jiangsu Yanshen Biological ... shareholders for a total,cash consideration of approximately ...
Cached Biology Technology:CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 2CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 3CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 4Agendia Opens CLIA-Registered U.S. Genomics Laboratory 2Agendia Opens CLIA-Registered U.S. Genomics Laboratory 3Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 2Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... have used ancient shorelines to predict the stability of today,s ... high shoreline from three million years ago, for example ... thought to be evidence of a high sea level due ... led many scientists to think that if the world,s largest ... just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the rapid, mysterious death of phytoplankton in the North ... Rutgers University and the Woods Hole Oceanographic Institution (WHOI). ... cancer research. The team discovered a previously unknown ... been attacking and killing Emiliania huxleyi , a ...
... A nutritionist whose research was instrumental in adding fruits and ... subsidy will receive the March of Dimes Agnes Higgins Award ... Gail Harrison, Ph.D., MNS, , a professor in ... California, Los Angeles School of Public Health, will receive the ...
... of a gene through deletion of genetic material on chromosome ... said a consortium of researchers led by Baylor College of ... today in the journal Nature Genetics . "This ... these problems in a specific group of individuals to this ...
Cached Biology News:Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Developmental delay could stem from nicotinic receptor deletion 2
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: